QF0159 Marketing Release Record

Product Specific Information
Please note that methacarn fixation produces optimal staining.
Human breast carcinoma: immunohistochemical staining for cyclin B1 using NCL-CYCLIN B1.
Note cytoplasmic staining of tumor cells. Paraffin section.
Novocastra Cyclin D1
Clone P2D11F11 Reference Range
1 mL, 0.1 mL lyophilized
NCL-CYCLIN D1-GM P (HIER/Enzyme) W IVD
1 mL liquid NCL-L-CYCLIN D1-GM P (HIER/Enzyme) W
7 mL ready-to-use RTU-CYCLIN D1-GM P (HIER/Enzyme)
Clone DCS-6
1 mL lyophilized NCL-CYCLIN D1 F P (HIER/Enzyme) W
Antigen Background
The D-type cyclins are a family of proteins which function primarily by
regulating the activity of cyclin dependent kinases in the G1 phase of the cell
cycle. Cyclin D1, a protein of 36 kD, is also known as PRAD1 or bcl-1.
Maximum expression of cyclin D1 occurs at a critical point in mid to late G1
phase of the cell cycle. The cyclin D1 gene, located on 11q13 has been
reported to be overexpressed in mantle cell lymphomas due to the
chromosomal translocation t(11;18). It has also been observed in approximately
30 percent of breast cancers.
Human breast carcinoma: immunohistochemical staining for cyclin D1 using
NCL-CYCLIN D1-GM. Note nuclear staining of a proportion of tumor cells. Paraffin section.
IVD
IVD
RUO*
Novocastra Cyclin D3
Clone DCS-22
1 mL lyophilized NCL-CYCLIN D3 F P (HIER) W
The 34 kD cyclin D3 protein shares 53 percent sequence homology with
cyclin D1. Cyclin D3 expression is reported to be induced later than cyclin D1
in G1 phase of the cell cycle. When complexed with cyclin dependent
kinases, cyclin D3 shows activity characteristic of other D-type cyclins.
However, an increase in cyclin D3 expression with an absence of kinase
activity has been observed in terminally differentiated, quiescent cells,
suggesting an additional role for cyclin D3.
Novocastra Cyclin E
Clone 13A3
1 mL lyophilized NCL-CYCLIN E ASR
Analyte Specific Reagent. Analytical and performance characteristics are
not established.
Novocastra Cyclin G
Clone 11C8
1 mL lyophilized NCL-CYCLIN G P (HIER) W
Cyclin G, a member of the cyclin family, is one of a number of proteins which
is a transcriptional target of the tumor suppressor, p53. Cyclin G appears to
be upregulated from early G1 to G1/S phase and is reported to be
constitutively expressed throughout the cell cycle in T and B cell lines. In
contrast, in stimulated peripheral T cells, cyclin G mRNA levels are highest
in early G1 phase and decline during cell cycle progression. Cyclin G
expression levels parallel p53 protein expression in murine B lymphocytes,
however, in several human Burkitt lymphomas and tissues of p53 null mice,
cyclin G expression levels can be both inverse to that of p53 levels or
expressed independently of p53 protein. In damaged neurons, an increase in
cyclin G mRNA expression has been shown in the early stages of nerve
regeneration and in situ hybridization has demonstrated cyclin G expression
in a restricted group of mature neurons, particularly in the telencephalon
and the thalamus. This constitutive expression in some cell types suggests
that cyclin G may have a function different from other members of the cyclin
group and that cyclin G expression is not predominantly regulated by p53
protein.
Novocastra Cytokeratin 1
Clone 34�B4
0.5 mL lyophilized NCL-CK1 F P (HIER)
Intermediate filaments, distinctive cytoskeletal components present in
virtually all mammalian cells are distinguished from other cytoskeletal
structures such as microtubules and microfilaments on the basis of filament
diameter and protein composition. Keratins are a complex class of
intermediate filaments with molecular weights ranging from 40 to 70 kD. At
least 20 different human cytokeratin peptides have been individually
characterized and catalogued. Cytokeratin 1 has a molecular weight of 68
kD and is present in complex epithelium.
Product Specific Information
NCL-CK1 reacts with squamous epithelium.
RUO*
RUO*
F Frozen I Immunofluorescence E Electron microscopy
P Paraffin C Flow cytometry O Other applications
W Western blotting
IVD
/51
Primary Antibodies